Automate Your Wheel Strategy on AMGN
With Tiblio's Option Bot, you can configure your own wheel strategy including AMGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AMGN
- Rev/Share 63.4312
- Book/Share 11.5372
- PB 26.3115
- Debt/Equity 9.2446
- CurrentRatio 1.1704
- ROIC 0.0953
- MktCap 163226033360.0
- FreeCF/Share 20.2881
- PFCF 14.9543
- PE 27.5266
- Debt/Assets 0.6421
- DivYield 0.0305
- ROE 0.9294
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AMGN | Guggenheim | -- | Neutral | -- | $288 | May 20, 2025 |
| Resumed | AMGN | Cantor Fitzgerald | -- | Neutral | -- | $305 | April 22, 2025 |
| Resumed | AMGN | BofA Securities | -- | Underperform | -- | $256 | Dec. 10, 2024 |
| Initiation | AMGN | Bernstein | -- | Outperform | -- | $380 | Oct. 17, 2024 |
| Downgrade | AMGN | Truist | Buy | Hold | $320 | $333 | Oct. 14, 2024 |
| Initiation | AMGN | Cantor Fitzgerald | -- | Overweight | -- | $405 | Sept. 27, 2024 |
News
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Read More
Amgen (AMGN) Just Flashed Golden Cross Signal: Do You Buy?
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen Inc. (AMGN) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, AMGN's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Read More
5 Dogs of the Dow Are Crushing the S&P 500 and Nasdaq in 2025
Published: July 28, 2025 by: 24/7 Wall Street
Sentiment: Neutral
The Dogs of the Dow is a well-known strategy first published in 1991 by Michael O'Higgins.
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
AMGN's deep pipeline and rare disease expansion may outweigh NVO's GLP-1 dominance and leadership shakeup.
Read More
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership Team Will spearhead clinical advancement of the company's innovative NLRP3 inflammasome inhibitor portfolio Brings deep clinical leadership in obesity and cardiometabolic diseases, with a proven track record guiding programs from early-stage development through Phase 3 and regulatory approval Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of chronic inflammatory diseases through selective modulation of the NLRP3 inflammasome, today announces the appointment of Dr. Jyothis George, M.D., Ph.D., …
Read More
Undercovered Dozen: Christian Dior, Coca-Cola, Trinity Capital, Amgen And More
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Neutral
This week's Undercovered Dozen spotlights 12 lesser-known stocks with compelling investment theses, spanning micro-nuclear, luxury, biotech, and high-yield BDCs. Highlighted opportunities include NANO Nuclear Energy's niche potential, Christian Dior SE's LVMH exposure, and Harrow's explosive growth in ophthalmic pharmaceuticals. Coca-Cola and Ares Capital are flagged as overvalued or increasingly risky, with warnings of unsustainable growth and looming corrections for investors.
Read More
Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
What Makes Amgen (AMGN) a New Buy Stock
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Negative
Here is how Amgen (AMGN) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
Published: July 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The latest trading day saw Amgen (AMGN) settling at $296.85, representing a +2.18% change from its previous close.
Read More
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
Published: July 02, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Amgen's gastric cancer drug meets late-stage trial goal
Published: June 30, 2025 by: Reuters
Sentiment: Positive
Amgen said on Monday its experimental cancer therapy, when combined with chemotherapy, met the main goal in a late-stage trial.
Read More
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen aims to challenge obesity drug leaders with MariTide, a potential monthly treatment now in late-stage trials.
Read More
Here's Why Amgen (AMGN) is a Strong Growth Stock
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here's Why Amgen (AMGN) is a Strong Value Stock
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
What's Happening With Amgen Stock?
Published: June 24, 2025 by: Forbes
Sentiment: Negative
Amgen stock (NASDAQ:AMGN) fell 6% on Monday, June 23, 2025, after mid-stage clinical trial results for its long-acting experimental obesity drug, MariTide, revealed a need for a low starting dose to mitigate side effects like vomiting. Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase with an eight-week dose escalation period.
Read More
Low start dose of Amgen experimental weight-loss drug limits side effects
Published: June 23, 2025 by: Reuters
Sentiment: Positive
People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-stage trial presented at a medical meeting on Monday.
Read More
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
MariTide, the First Monthly or Less Frequently Dosed Obesity Treatment, Demonstrated Up to ~20% Average Weight Loss Without a Weight Loss Plateau, and Delivered Significant Cardiometabolic Improvements at 52 Weeks In People Living With Obesity With Type 2 Diabetes, MariTide Demonstrated Up to ~17% Average Weight Loss and Robust HbA1c Improvements Dose Escalation With Lower Starting Doses Substantially Improved Gastrointestinal Tolerability, Without Compromising Efficacy The MARITIME Phase 3 Chronic Weight Management Studies are Actively Enrolling, and Phase 3 Studies in People Living With Atherosclerotic Cardiovascular Disease, Heart Failure and Obstructive Sleep Apnea Will be Initiated in 2025 THOUSAND OAKS, Calif. …
Read More
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Here's Why Amgen (AMGN) is a Strong Momentum Stock
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Why Amgen (AMGN) is a Top Growth Stock for the Long-Term
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Why Amgen (AMGN) is a Top Value Stock for the Long-Term
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
Read More
Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies
Published: June 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Amgen faces major revenue risk from upcoming patent cliffs but has promising pipeline drugs like MariTide and olpasiran to offset losses. Recent financials show solid revenue growth and improved margins, though net selling prices and legacy drugs like Enbrel remain under pressure. Valuation analysis reveals AMGN is priced for no growth, offering 27% upside if the company achieves even modest revenue increases.
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Amgen's Imdelltra Cuts Lung Cancer Death Risk by 40% in Phase III
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Negative
AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.
Read More
About Amgen Inc. (AMGN)
- IPO Date 1983-06-17
- Website https://www.amgen.com
- Industry Drug Manufacturers - General
- CEO Robert A. Bradway
- Employees 28000